PD-L1xVEGF Bispecific: 1st Global Data from BioNTech/BMS
BioNTech and BMS reveal promising first-in-human global data for their novel PD-L1xVEGF bispecific antibody, showing potential in treating advanced solid tumors.
immunotherapy
Read More
new promising os trend: Summit’s Phase 3 global data
Explore the latest global data from Summit’s PD-1xVEGF clinical trial, revealing a new promising OS trend for patients. See how this breakthrough could change care.